Home › Idiopathic Pulmonary Fibrosis › Colorado › Aurora
Idiopathic Pulmonary Fibrosis clinical trials in Aurora, CO
6 studies for Idiopathic Pulmonary Fibrosis are looking for participants at sites in and around Aurora (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
RecruitingPhase 2
- University of Colorado, Anschutz Medical Campus, Aurora
A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
RecruitingPhase 2
- Research Site, Aurora
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
RecruitingPhase 2
- University of Colorado, Aurora
Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
RecruitingObservational study
- University of Colorado, Aurora
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
RecruitingObservational study
- University of Colorado - Anschutz Medical Campus, Aurora
The Genetics of Pulmonary Fibrosis
RecruitingObservational studyHealthy volunteers welcome
- University of Colorado Anschutz Medical Campus, Aurora
Idiopathic Pulmonary Fibrosis trials in other cities
- Birmingham, AL9 studies
- New York City, NY8 studies
- Kansas City, KS7 studies
- Los Angeles, CA7 studies
- Philadelphia, PA7 studies
- Chicago, IL6 studies
- Durham, NC6 studies
- Nashville, TN5 studies
- Dallas, TX5 studies
- Charleston, SC5 studies
- Atlanta, GA5 studies
- Houston, TX5 studies
Other studies in Aurora
- Cancer (all types)35 studies
- Colorectal Cancer32 studies
- Non-Small Cell Lung Cancer31 studies
- Breast Cancer28 studies
- Ovarian Cancer25 studies
- Metastatic Cancer25 studies
- Type 1 Diabetes23 studies
- Obesity22 studies
- Prostate Cancer19 studies
- Lung Cancer19 studies
- Heart Failure18 studies
- Melanoma18 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.